Beranda › Limfoma Burkitt › Virginia › Charlottesville
Uji klinis Limfoma Burkitt di Charlottesville, VA
3 studi untuk Limfoma Burkitt mencari peserta di lokasi sekitar Charlottesville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 2
- University of Virginia Cancer Center, Charlottesville
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Menerima pesertaFase 2
- University of Virginia Cancer Center, Charlottesville
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
- University of Virginia Cancer Center, Charlottesville
Uji klinis Limfoma Burkitt di kota lain
- Houston, TX21 studi
- Milwaukee, WI16 studi
- Philadelphia, PA16 studi
- New York City, NY14 studi
- Chicago, IL14 studi
- Cincinnati, OH12 studi
- Atlanta, GA12 studi
- Seattle, WA11 studi
- Durham, NC10 studi
- Boston, MA10 studi
- Los Angeles, CA10 studi
- Aurora, CO10 studi
Studi lain di Charlottesville
- Kanker Paru Non-Sel Kecil21 studi
- Leukemia Mieloid Akut16 studi
- Kanker Prostat15 studi
- Kanker Metastatik13 studi
- Kanker Endometrium13 studi
- Kanker (semua jenis)13 studi
- Kanker Paru13 studi
- Gagal Jantung11 studi
- Kanker Ovarium10 studi
- Kanker Kolorektal10 studi
- Diabetes Tipe 19 studi
- Kanker Payudara9 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.